<DOC>
	<DOC>NCT02032173</DOC>
	<brief_summary>To evaluate a new treatment regimen with a spaced out follow-up after an initial intensive treatment phase in patients with reduced visual acuity due to diabetic macular edema (DME).</brief_summary>
	<brief_title>Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Type I or type II diabetes with HbA1c≤10% Visual impairment due to a diabetic macular edema Stable antidiabetic treatment (since more than 3 months) or hygienedietary Inflammation or infection in one eye Women of childbearing potential without an efficient contraception, pregnant or breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ranibizumab</keyword>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>